ClinicalTrials.gg
CompletedNCT00405756Updated Jan 11, 2017Results posted

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

A Phase 3 interventional study of Lenalidomide: Double-blind Induction and Melphalan in Newly Diagnosed Multiple Myeloma, sponsored by Celgene Corporation. Completed at 98 sites in 22 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
459
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
21st of 249
459 · median 50
Started
2007
with 14 others
Phase 3
44 of 249
3 open now
Registered
19th of 249
by date
Lead sponsor
6 of 249
Celgene Corporation

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 21st largest by enrollment, is one of 15 that started in 2007, is one of 44 in phase 3, and was the 19th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.

Read the detailed description

The three phases for the study as originally defined and as represented in the results of 11 May 2010 are:

Double-blind Treatment Phase: Induction Melphalan/prednisone and lenalidomide 10 mg (MPR) (2 treatment arms), or melphalan/prednisone and placebo (MPp) (1 treatment arm) for up to 9 cycles. If disease progression, subjects have the option to enter into the Open-Label Extension Phase. There is also an option to enter into the Follow-Up Phase. If the disease has not progressed, subject can continue on blinded therapy into Maintenance.

Double-blind Treatment Phase: Maintenance One MPR treatment arm (MPR+R) will continue taking lenalidomide 10 mg in Maintenance. The other MPR treatment arm (MPR+p) will take placebo in Maintenance. The MP p treatment arm will take placebo in Maintenance (MPp+p). If disease progression, subjects have the option to enter the Open-Label Extension Phase to obtain treatment with lenalidomide, or to enter into the Follow-up Phase.

Open-label Extension Phase:

Treatment consists of oral lenalidomide (up to 25 mg) with or without dexamethasone until disease progression or treatment is discontinued for any reason until all study subjects are followed for at least 5 years from the date of randomization or have died. Subjects who discontinue from the Open-Label Extension Phase prior to completing a total of 5 years in the study will enter the Follow-up Phase.

Follow-up Phase:

Subjects are followed for overall survival and subsequent anti-myeloma treatment regimens until all subjects in this study are followed for at least 5 years from randomization or have died.

The pre-planned interim analysis for the Independent Data Monitoring Committee (IDMC) showed that the difference in progression-free survival (PFS) between treatment arms MPR+R and MPp+p (the defined primary comparative analysis for this study) surpassed the pre-specified O'Brien-Fleming boundary for superiority. The IDMC recommended the release of this information to the sponsor and also recommended that all patient and physician study participants receive information concerning the full findings of the MM-015 interim analysis. Therefore, due to these recommendations from the IDMC, treatment-arm codes were sent to the clinical trial centers to unblind the treatment arms of their study subjects once the amended protocol was reviewed and approved by the respective country Health Authorities and Ethics Committees. Subject participation in the MM-015 study continued after unblinding to obtain long-term data for all study endpoints, including overall survival.

When the study was unblinded, subjects still on protocol therapy had completed the Double-Blind Induction, and were on monotherapy in Double-Blind Maintenance. Subjects in arm MPR+R continued their monotherapy on lenalidomide. Subjects in arms MPR+p and MPp+p discontinued their placebo monotherapy and went into an observation period in which no antimyeloma therapy was taken. If disease progressed for any subject, the investigator had the option of entering the subject in Open Label Extension Phase to receive lenalidomide therapy (up to 25 mg daily) or the Follow-up Phase. All subjects were to be followed for at least 5 years from the start of the study.

03

Conditions studied

  • Newly Diagnosed Multiple Myeloma

Browse trials for

Keywords

  • Newly Diagnosed Multiple Myeloma
  • Celgene
  • CC-5013
  • Revlimid
  • Lenalidomide
  • Melphalan
  • Prednisone
  • Elderly
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must understand and voluntarily sign an form
  2. Age greater than or equal to 65 years at the time of signing the informed consent
  3. Newly diagnosed with symptomatic multiple myeloma as defined by the 3 criteria below:

MM diagnostic criteria (all of next 3 required)

  1. Monoclonal plasma cells in the bone marrow greater than or equal to 10% and/or presence of a -proven plasmacytoma
  2. Monoclonal protein present in the serum and/or urine
  3. Myeloma-related organ dysfunction (at least one of the following) [C] Calcium elevation in the blood (serum calcium >10.5mg/dl or ) [R] Renal insufficiency (serum creatinine >2mg/dl) [A] Anemia ( \<10g/dl or 2g \< normal) [B] Lytic bone lesions or osteoporosis AND have as defined by the following; IgG multiple myeloma: Serum monoclonal paraprotein (M-protein) level greater than or equal to 1.0 g/dL or urine M-protein level greater than or equal to 200 mg/24 hours IgA multiple myeloma: Serum M-protein level greater than or equal to 0.5 g/dL or urine M-protein level greater than or equal to 200 mg/24 hours IgD multiple myeloma: Serum M-protein level greater than or equal to 0.05 g/dL or urine M-protein level greater than or equal to 200 mg/24 hours Light chain multiple myeloma: Serum M-protein level greater than or equal to 1.0 g/dL or urine M-protein level greater than or equal to 200 mg/24 hours IgM multiple myeloma (IgM M-protein plus lytic bone disease documented by skeletal survey plain films): Serum M-protein level greater than or equal to 1.0g/dL or urine M-protein level greater than or equal to 200mg/24hours
  4. performance status greater than or equal to 60%.
  5. Able to adhere to the study visit schedule and other protocol requirements.
  6. Women of (WCBP) must:

    a. Have a negative medically supervised pregnancy test prior to the start of study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the subject practices and continues sexual abstinence.

    b Either commit to continued abstinence from heterosexual intercourse (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, effective without interruption, 28 days prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy.

  7. Males Subjects must:

    1. Agree to use a condom during sexual contact with a WCBP, even if they have had a vasectomy, throughout study drug therapy, during any dose interruption and after the cessation of study therapy.
    2. Agree to not donate semen during study drug therapy and for a period after end of study drug therapy.
  8. All subjects must

    1. Have an understanding that the study drug could have potential teratogenic risk.
    2. Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy.
    3. Agree not to share study medication with another person.
    4. All patients must be counseled about pregnancy precautions and risks of fetal exposure.

Female Subjects:

Females of childbearing potential (FCBP) with regular cycles must agree to have pregnancy tests weekly for the first 28 days of study participation and then every 28 days while on study, at study discontinuation, and at day 28 following discontinuation from the study. If menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28 days and then every 14 days while on study, at study discontinuation, and at days 14 and 28 following discontinuation from the study.

In addition to the required pregnancy testing, the Investigator must confirm with FCBP that she is continuing to use two reliable methods of birth control at each visit. Counseling about pregnancy precautions and the potential risks of fetal exposure must be conducted at a minimum of every 28 days. During counseling, subjects must be reminded to not share study drug and to not donate blood.

Pregnancy testing and counseling must be performed if a subject misses her period or if her pregnancy test or her menstrual bleeding is abnormal. Study drug treatment must be discontinued during this evaluation.

Females must agree to abstain from breastfeeding during study participation and for at least 28 days after the discontinuation from the study.

Male Subjects:

Counseling about the requirement for latex condom use during sexual contact with females of childbearing potential and the potential risks of fetal exposure must be conducted at a minimum of every 28 days. During counseling, subjects must be reminded to not share study drug and to not donate blood, sperm, or semen.

If pregnancy or a positive pregnancy test does occur in a study subject or the partner of a study subject during study participation, study drug must be immediately discontinued.

Exclusion criteria

Exclusion Criteria

  1. Previous treatment with antimyeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of [i.e., less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 28 days [4 weeks] of randomization]).
  2. Any serious medical condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he or she participates in this study or confounds experimental the ability to interpret data from the study.
  3. Pregnant or lactating females.
  4. Radiotherapy within 14 days (2 weeks) of randomization.
  5. Plasmapheresis within 28 days (4 weeks) of randomization.
  6. Any of the following laboratory abnormalities:

    (ANC) \< 1,500 cells/mL (1.5*10\^9/L) count \< 75,000 cells/uL (75*10\^9/L) for subjects in whom \< 50% of bone marrow nucleated cells are plasma cells; but platelet count \<30,000/uL for subjects in whom >= 50% of bone marrow nucleated cells are plasma cells \< 8.0 g/dL (80 g/L) Serum creatinine > 2.5 mg/dL (221 µmol/L) Serum (SGOT/AST) or alanine aminotransferase (SGPT/ALT) > 3.0 times (ULN)

  7. Prior history of , other than multiple myeloma, unless the subject has been free of the disease for greater than or equal to 3 years.

    Exceptions include the following:

    Basal cell carcinoma of the skin Squamous cell carcinoma of the skin Carcinoma in situ of the cervix Carcinoma in situ of the breast Incidental histologic finding of prostate cancer (TNM Classification of Malignant Tumours (TNM) stage of T1a or T1b)

  8. Neuropathy of >= grade 2 severity.
  9. Known (HIV) positivity or active infectious hepatitis, type A, B or C.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
459 participants (actual)

Study arms

  • Experimental
    MPR+R

    Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.

    Drug: Lenalidomide: Double-blind Induction · Drug: Melphalan · Drug: Prednisone · Drug: Aspirin · Drug: Lenalidomide: Double-blind Maintenance · Drug: Lenalidomide: Open-label

  • Experimental
    MPR+p

    Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.

    Drug: Lenalidomide: Double-blind Induction · Drug: Melphalan · Drug: Prednisone · Drug: Aspirin · Drug: Placebo · Drug: Lenalidomide: Open-label

  • Other
    MPp+p

    Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.

    Drug: Melphalan · Drug: Prednisone · Drug: Aspirin · Drug: Placebo · Drug: Lenalidomide: Open-label

Interventions

  • Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

    Also known as: Revlimid

  • Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

    Also known as: Alkeran

  • Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

  • Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms. Double-blind maintenance: at the investigator's discretion

  • DrugPlacebo

    Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles. Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.

  • Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.

    Also known as: Revlimid

  • Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)

    Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

    Time frame: up to 165 weeks

Secondary outcomes

  1. Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)

    Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

    Time frame: Approximately week 37 (start of cycle 10) to week 165

  2. Kaplan Meier Estimates of Overall Survival (OS)

    Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier.

    Time frame: up to 177 weeks

  3. Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)

    Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

    Time frame: up to 165 weeks

  4. Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period

    Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus \>=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE).

    Time frame: Up to 165 weeks

  5. Time to First Response

    Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria.

    Time frame: Up to 66 weeks

  6. Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)

    Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

    Time frame: Up to 149 weeks

  7. Kaplan Meier Estimates for Time to Next Antimyeloma Therapy

    Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.

    Time frame: Up to 168 weeks

  8. Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period

    Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption.

    Time frame: Up to 169 weeks (Double-blind therapy period plus 4 weeks)

  9. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale

    Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  10. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  11. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  12. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  13. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  14. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  15. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  16. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  17. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  18. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  19. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  20. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  21. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  22. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  23. Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  24. Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  25. Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  26. Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

  27. Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale

    Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image.

    Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16

07

Results

Posted May 11, 2012

Participant flow

Data represents a May 11, 2010 data cut-off. The study is ongoing.

Double-blind Treatment
Participant flow — Double-blind Treatment
MilestoneMPR+RMPR+pMPp+p
Started152153154
Safety population150152153
Completed000
Not completed152153154
Withdrew: Ongoing in double-blind treatment452418
Withdrew: Adverse event312712
Withdrew: Disease progression4781102
Withdrew: Lack of efficacy142
Withdrew: Withdrawal by subject15910
Withdrew: Lost to follow-up100
Withdrew: Death444
Withdrew: Protocol violation102
Withdrew: Other744
Open-label Extension
Participant flow — Open-label Extension
MilestoneMPR+RMPR+pMPp+p
Started194772
Completed000
Not completed194772
Withdrew: Ongoing in open label period71525
Withdrew: Adverse event137
Withdrew: Disease progression82326
Withdrew: Withdrawal by subject233
Withdrew: Death124
Withdrew: Other017
Follow-up
Participant flow — Follow-up
MilestoneMPR+RMPR+pMPp+p
Started759088
Completed000
Not completed759088
Withdrew: Ongoing in follow-up period525160
Withdrew: Death213124
Withdrew: Lost to follow-up284

Outcome measures

PrimaryKaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)

Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Time frame:
up to 165 weeks
Reported as:
Median · weeks
Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)
weeksMPR+RMPR+pMPp+p
Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)136.1 (86.14 to NA)62.1 (56.14 to 72.14)56.1 (52.14 to 68.14)
Statistical analysis
  • MPR+R vs MPp+p · Log Rank · p = <0.001 (The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.395 · 95% CI 0.278 to 0.560
  • MPR+R vs MPR+p · Log Rank · p = <0.001 (The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.494 · 95% CI 0.347 to 0.702
  • MPR+p vs MPp+p · Log Rank · p = 0.134 (The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.796 · 95% CI 0.589 to 1.075
SecondaryKaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)

Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Time frame:
Approximately week 37 (start of cycle 10) to week 165
Reported as:
Median · weeks
Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)
weeksMPR+RMPR+p
Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)112.0 (83.29 to NA)32.3 (23.57 to 52.14)
Statistical analysis
  • MPR+R vs MPR+p · Log Rank · p = <0.001 · Hazard ratio (hr): 0.340 · 95% CI 0.214 to 0.541P-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.
SecondaryKaplan Meier Estimates of Overall Survival (OS)

Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier.

Time frame:
up to 177 weeks
Reported as:
Median · weeks
Kaplan Meier Estimates of Overall Survival (OS)
weeksMPR+RMPR+pMPp+p
Kaplan Meier Estimates of Overall Survival (OS)NA (NA to NA)NA (148.43 to NA)NA (NA to NA)
SecondaryKaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)

Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Time frame:
up to 165 weeks
Reported as:
Median · weeks
Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)
weeksMPR+RMPR+pMPp+p
Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)148.1 (100.00 to NA)62.7 (57.14 to 74.14)61.3 (52.29 to 70.14)
Statistical analysis
  • MPR+R vs MPp+p · Log Rank · p = <0.001 (The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.337 · 95% CI 0.231 to 0.493
  • MPR+R vs MPR+p · Log Rank · p = <0.001 (The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.414 · 95% CI 0.284 to 0.603
  • MPR+p vs MPp+p · Log Rank · p = 0.223 (The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.826 · 95% CI 0.606 to 1.125
SecondaryNumber of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period

Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus \>=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE).

Time frame:
Up to 165 weeks
Reported as:
Number · participants
Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period
participantsMPR+RMPR+pMPp+p
Complete response (CR)1555
Partial response (PR)1029972
Stable disease (SD)284070
Progressive disease (PD)020
Response not evaluable (NE)777
Statistical analysis
  • MPR+R vs MPp+p · Wilcoxon (Mann-Whitney) · p = <0.001 (P-value calculation excludes the category - Response not evaluable (NE))
  • MPR+R vs MPR+p · Wilcoxon (Mann-Whitney) · p = 0.009 (P-value calculation excludes the category - Response not evaluable (NE))
  • MPR+p vs MPp+p · Wilcoxon (Mann-Whitney) · p = 0.003 (P-value calculation excludes the category - Response not evaluable (NE))
  • MPR+R vs MPp+p · Fisher Exact · p = <0.001 · Odds ratio (or): 3.34 · 95% CI 2.04 to 5.47
  • MPR+R vs MPR+p · Fisher Exact · p = 0.096 · Odds ratio (or): 1.58 · 95% CI 0.95 to 2.62
  • MPR+p vs MPp+p · Fisher Exact · p = 0.002 · Odds ratio (or): 2.12 · 95% CI 1.33 to 3.37
SecondaryTime to First Response

Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria.

Time frame:
Up to 66 weeks
Reported as:
Mean · weeks
Time to First Response
weeksMPR+RMPR+pMPp+p
Time to First Response10.0 ± 7.409.3 ± 6.5516.2 ± 11.59
SecondaryKaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)

Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Time frame:
Up to 149 weeks
Reported as:
Median · weeks
Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)
weeksMPR+RMPR+pMPp+p
Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)121.6 (96.00 to NA)56.1 (52.14 to 64.29)55.4 (44.14 to 76.14)
Statistical analysis
  • MPR+R vs MPp+p · Log Rank · p = <0.001 (The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.348 · 95% CI 0.228 to 0.531
  • MPR+R vs MPR+p · Log Rank · p = <0.001 (The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.419 · 95% CI 0.281 to 0.623
  • MPR+p vs MPp+p · Log Rank · p = 0.302 (The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.825 · 95% CI 0.571 to 1.191
SecondaryKaplan Meier Estimates for Time to Next Antimyeloma Therapy

Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.

Time frame:
Up to 168 weeks
Reported as:
Median · weeks
Kaplan Meier Estimates for Time to Next Antimyeloma Therapy
weeksMPR+RMPR+pMPp+p
Kaplan Meier Estimates for Time to Next Antimyeloma Therapy128.9 (99.86 to NA)66.1 (60.14 to 76.00)66.3 (61.14 to 72.43)
Statistical analysis
  • MPR+R vs MPp+p · Log Rank · p = <0.001 (The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.404 · 95% CI 0.296 to 0.553
  • MPR+R vs MPR+p · Log Rank · p = <0.001 (The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.499 · 95% CI 0.363 to 0.688
  • MPR+p vs MPp+p · Log Rank · p = 0.169 (The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.) · Hazard ratio (hr): 0.827 · 95% CI 0.630 to 1.085
SecondarySummary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period

Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption.

Time frame:
Up to 169 weeks (Double-blind therapy period plus 4 weeks)
Reported as:
Number · participants
Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period
participantsMPR+RMPR+pMPp+p
>=1 adverse event (AE)150151153
>=1 CTCAE grade 3-4 AE137129107
>=1 CTCAE grade 5 AE767
>=1 serious AE (SAE)666256
>=1 AE related to Lenaldomide/Placebo148145131
>=1 AE related to Melphalan140134126
>=1AE related to Prednisone879493
>=1 Grade 3-4 AE related to Lenaldomide/Placebo12811768
>=1 Grade 3-4 AE related to Melphalan11811062
>=1 Grade 3-4 AE related to Prednisone322922
>=1 Grade 5 AE related to Lenalidomide/Placebo322
>=1 Grade 5 AE related to Melphalan313
>=1 Grade 5 AE related to Prednisone111
>=1 SAE related to Lenalidomide/Placebo383211
>=1 SAE related to Melphalan272411
>=1 SAE related to Prednisone19165
>=1 AE leading to Lenalidomide/Placebo withdrawal262414
>=1 AE leading to Melphalan withdrawal201910
>=1 AE leading to Prednisone withdrawal201910
>=1 AE leading to Lenalidomide/Plac dose reduction717026
>=1 AE leading to Melphalan dose reduction475821
>=1 AE leading to Prednisone dose reduction1575
>=1 AE leading to Lenalidomide/Plac dose interrupt928251
>=1 AE leading to Melphalan dose interruption510
>=1 AE leading to Prednisone dose interruption283915
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale

Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=114,121,125)2.3 ± 26.135.6 ± 18.866.1 ± 19.41
Cycle 7 - approximately Month 7 (n=96,108,110)8.0 ± 24.958.1 ± 22.484.2 ± 23.92
Cycle 10 - approximately Month 10 (n=84,86,96)12.4 ± 25.338.8 ± 24.706.2 ± 24.60
Cycle 13 - approximately Month 13 (n=70,70,82)7.6 ± 28.328.8 ± 24.025.4 ± 22.80
Cycle 16 - approximately Month 16 (n=61,50,62)10.7 ± 25.287.2 ± 26.298.1 ± 25.11
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=120,127,130)1.9 ± 23.723.3 ± 21.644.5 ± 18.68
Cycle 7 - approximately Month 7 (n=100,112,112)8.2 ± 22.718.1 ± 20.542.7 ± 23.20
Cycle 10 - approximately Month 10 (n=88,95,96)8.9 ± 22.758.5 ± 25.625.1 ± 20.42
Cycle 13 - approximately Month 13 (n=75,74,83)8.6 ± 24.049.7 ± 25.393.3 ± 20.30
Cycle 16 - approximately Month 16 (n=64,53,63)10.0 ± 25.007.6 ± 22.661.1 ± 19.30
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=119,127,130)1.8 ± 33.183.0 ± 30.757.4 ± 26.34
Cycle 7 - approximately Month 7 (n=99,112,113)5.7 ± 35.578.0 ± 32.426.9 ± 31.16
Cycle 10 - approximately Month 10 (n=86,95,95)9.3 ± 35.767.5 ± 36.295.6 ± 31.29
Cycle 13 - approximately Month 13 (n=74,74,82)9.7 ± 40.3611.7 ± 33.425.7 ± 30.68
Cycle 16 - approximately Month 16 (n=64,53,63)12.2 ± 40.098.5 ± 34.227.1 ± 31.93
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=115,125,128)4.8 ± 25.002.7 ± 22.596.8 ± 18.75
Cycle 7 - approximately Month 7 (n=98,111,112)8.8 ± 24.944.2 ± 20.385.0 ± 21.56
Cycle 10 - approximately Month 10 (n=86,92,97)9.0 ± 23.281.6 ± 22.074.7 ± 22.05
Cycle 13 - approximately Month 13 (n=73,73,83)8.2 ± 24.591.1 ± 21.786.6 ± 21.78
Cycle 16 - approximately Month 16 (n=63,52,63)9.9 ± 23.23-0.2 ± 21.576.9 ± 19.72
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=115,125,128)0.3 ± 21.51-2.0 ± 21.331.3 ± 16.68
Cycle 7 - approximately Month 7 (n=98,111,113)2.9 ± 22.310.1 ± 17.330.7 ± 18.42
Cycle 10 - approximately Month 10 (n=87,92,97)1.0 ± 22.64-4.4 ± 19.89-2.7 ± 20.65
Cycle 13 - approximately Month 13 (n=73,73,83)-0.0 ± 21.34-3.0 ± 23.78-1.4 ± 17.69
Cycle 16 - approximately Month 16 (n=63,52,63)0.3 ± 22.29-3.5 ± 27.48-4.0 ± 18.13
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=115,125,127)5.1 ± 35.050.3 ± 26.606.0 ± 22.78
Cycle 7 - approximately Month 7 (n=98,111,112)8.3 ± 33.874.4 ± 24.486.1 ± 26.57
Cycle 10 - approximately Month 10 (n=87,92,97)10.9 ± 34.274.5 ± 29.874.1 ± 27.22
Cycle 13 - approximately Month 13 (n=72,73,83)11.8 ± 32.917.5 ± 29.806.2 ± 27.63
Cycle 16 - approximately Month 16 (n=63,52,63)13.2 ± 33.356.1 ± 30.799.8 ± 28.66
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=120,127,129)-3.0 ± 25.61-5.5 ± 24.08-5.1 ± 24.33
Cycle 7 - approximately Month 7 (n=100,112,110)-7.6 ± 23.00-9.5 ± 25.97-5.7 ± 27.32
Cycle 10 - approximately Month 10 (n=87,95,95)-7.5 ± 27.31-7.5 ± 29.78-6.9 ± 28.31
Cycle 13 - approximately Month 13 (n=74,74,82)-7.1 ± 26.08-10.7 ± 30.33-7.5 ± 27.29
Cycle 16 - approximately Month 16 (n=64,53,62)-10.0 ± 26.86-9.7 ± 28.77-4.1 ± 26.34
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=120,127,130)3.3 ± 19.40-1.3 ± 17.14-0.0 ± 17.36
Cycle 7 - approximately Month 7 (n=99,112,112)0.5 ± 14.57-0.7 ± 19.940.7 ± 14.73
Cycle 10 - approximately Month 10 (n=87,95,97)1.9 ± 16.75-1.4 ± 19.400.3 ± 14.23
Cycle 13 - approximately Month 13 (n=75,72,83)0.7 ± 13.55-3.0 ± 19.65-0.4 ± 12.48
Cycle 16 - approximately Month 16 (n=64,52,62)1.0 ± 12.90-4.2 ± 18.65-1.3 ± 9.21
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=120,127,129)-14.4 ± 32.76-13.8 ± 33.60-13.4 ± 29.32
Cycle 7 - approximately Month 7 (n=100,112,113)-17.8 ± 36.18-16.5 ± 33.45-11.5 ± 33.49
Cycle 10 - approximately Month 10 (n=88,95,97)-17.2 ± 34.78-15.6 ± 35.30-9.8 ± 31.71
Cycle 13 - approximately Month 13 (n=74,74,83)-13.7 ± 40.48-14.9 ± 33.28-12.1 ± 27.46
Cycle 16 - approximately Month 16 (n=64,53,63)-20.3 ± 33.92-11.0 ± 33.00-12.2 ± 29.96
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=117,126,126)-2.6 ± 29.74-6.4 ± 32.04-0.0 ± 23.48
Cycle 7 - approximately Month 7 (n=100,110,110)-1.7 ± 28.18-8.5 ± 32.072.1 ± 20.82
Cycle 10 - approximately Month 10 (n=86,93,96)-4.3 ± 30.60-4.3 ± 35.873.8 ± 25.07
Cycle 13 - approximately Month 13 (n=73,73,81)-5.0 ± 30.26-2.3 ± 30.60-0.0 ± 22.35
Cycle 16 - approximately Month 16 (n=62,53,62)-3.2 ± 29.39-6.3 ± 32.071.6 ± 22.92
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=118,124,128)2.0 ± 33.56-1.6 ± 31.77-5.0 ± 27.77
Cycle 7 - approximately Month 7 (n=100,109,111)-1.0 ± 29.76-6.4 ± 27.02-5.7 ± 32.06
Cycle 10 - approximately Month 10 (n=87,94,96)-5.0 ± 28.99-2.5 ± 25.04-1.7 ± 32.58
Cycle 13 - approximately Month 13 (n=75,73,83)-4.9 ± 29.860.9 ± 29.38-6.8 ± 29.80
Cycle 16 - approximately Month 16 (n=64,53,63)-4.7 ± 32.46-0.6 ± 32.36-3.7 ± 31.18
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=119,125,130)1.7 ± 36.541.9 ± 34.73-5.6 ± 25.96
Cycle 7 - approximately Month 7 (n=99,111,111)-3.7 ± 33.64-5.7 ± 31.75-5.7 ± 27.66
Cycle 10 - approximately Month 10 (n=87,93,96)-5.0 ± 33.15-5.4 ± 29.20-8.0 ± 29.32
Cycle 13 - approximately Month 13 (n=75,72,83)-6.2 ± 36.23-8.8 ± 30.13-4.8 ± 32.15
Cycle 16 - approximately Month 16 (n=64,52,63)-7.8 ± 36.01-16.0 ± 35.24-6.4 ± 28.62
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=114,124,128)-1.8 ± 34.314.8 ± 30.86-4.9 ± 27.45
Cycle 7 - approximately Month 7 (n=96,111,112)-3.5 ± 36.350.6 ± 30.14-2.7 ± 31.05
Cycle 10 - approximately Month 10 (n=86,93,97)-5.0 ± 34.88-1.1 ± 28.43-1.7 ± 26.95
Cycle 13 - approximately Month 13 (n=73,73,81)-5.0 ± 31.27-2.7 ± 28.74-3.3 ± 29.16
Cycle 16 - approximately Month 16 (n=63,51,62)-1.6 ± 31.36-5.2 ± 30.82-2.2 ± 32.44
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=115,125,124)2.3 ± 28.851.9 ± 24.063.2 ± 25.65
Cycle 7 - approximately Month 7 (n=98,109,112)3.4 ± 25.54-1.2 ± 23.090.9 ± 22.13
Cycle 10 - approximately Month 10 (n=87,92,95)1.1 ± 22.981.4 ± 20.91-0.0 ± 21.19
Cycle 13 - approximately Month 13 (n=73,73,80)5.5 ± 30.43-1.4 ± 18.780.8 ± 18.35
Cycle 16 - approximately Month 16 (n=63,52,61)10.6 ± 35.831.3 ± 19.750.5 ± 17.74
SecondaryChange From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=111,123,125)2.4 ± 24.91-1.1 ± 19.06-2.9 ± 18.93
Cycle 7 - approximately Month 7 (n=94,111,112)2.1 ± 23.85-0.6 ± 28.07-2.1 ± 22.50
Cycle 10 - approximately Month 10 (n=84,92,97)6.0 ± 21.440.7 ± 28.81-1.7 ± 19.47
Cycle 13 - approximately Month 13 (n=70,72,83)4.8 ± 21.45-0.5 ± 28.80-4.0 ± 26.75
Cycle 16 - approximately Month 16 (n=61,52,63)1.6 ± 20.58-0.6 ± 35.24-5.3 ± 30.06
SecondaryChange From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=113,121,127)-8.9 ± 19.56-8.7 ± 19.13-5.4 ± 15.83
Cycle 7 - approximately Month 7 (n=96,109,112)-9.0 ± 20.64-9.7 ± 23.25-6.0 ± 20.81
Cycle 10 - approximately Month 10 (n=85,91,95)-7.9 ± 23.00-7.1 ± 23.85-5.4 ± 18.79
Cycle 13 - approximately Month 13 (n=72,73,82)-7.2 ± 25.91-8.8 ± 24.90-6.3 ± 21.84
Cycle 16 - approximately Month 16 (n=62,51,62)-10.5 ± 23.87-5.9 ± 25.79-3.3 ± 20.67
SecondaryChange From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=113,120,125)1.3 ± 13.370.1 ± 13.280.6 ± 12.67
Cycle 7 - approximately Month 7 (n=95,108,111)0.4 ± 15.22-1.7 ± 14.271.8 ± 12.94
Cycle 10 - approximately Month 10 (n=85,89,94)-1.6 ± 14.460.0 ± 15.990.3 ± 12.61
Cycle 13 - approximately Month 13 (n=72,72,81)-3.8 ± 15.61-1.0 ± 14.590.3 ± 12.60
Cycle 16 - approximately Month 16 (n=62,50,61)-2.1 ± 14.95-2.9 ± 14.16-0.9 ± 12.23
SecondaryChange From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=112,121,124)4.7 ± 23.744.3 ± 23.567.6 ± 22.38
Cycle 7 - approximately Month 7 (n=93,108,112)14.6 ± 24.457.7 ± 23.869.8 ± 20.62
Cycle 10 - approximately Month 10 (n=83,88,97)17.3 ± 27.846.6 ± 22.4014.5 ± 21.73
Cycle 13 - approximately Month 13 (n=71,73,81)17.3 ± 27.156.3 ± 23.7811.9 ± 24.67
Cycle 16 - approximately Month 16 (n=62,52,62)18.5 ± 25.307.7 ± 28.4914.4 ± 26.62
SecondaryChange From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale

Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image.

Time frame:
Baseline (Day 0), Months 4, 7, 10, 13, 16
Reported as:
Mean · units on a scale
Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale
units on a scaleMPR+RMPR+pMPp+p
Cycle 4 - approximately Month 4 (n=110,117,119)2.1 ± 35.36-0.3 ± 37.274.5 ± 25.65
Cycle 7 - approximately Month 7 (n=88,104,108)3.8 ± 33.322.6 ± 37.945.2 ± 27.78
Cycle 10 - approximately Month 10 (n=79,83,94)7.6 ± 33.32-4.0 ± 43.693.9 ± 26.72
Cycle 13 - approximately Month 13 (n=68,72,79)1.0 ± 31.01-0.5 ± 44.235.1 ± 32.51
Cycle 16 - approximately Month 16 (n=59,52,61)3.4 ± 32.586.4 ± 41.252.7 ± 28.08

Adverse events

Collected over Up to 169 weeks (Double-blind therapy period plus 4 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MPR+R—66/150 (44%)149/150 (99.3%)
MPR+p—62/152 (40.8%)151/152 (99.3%)
MPp+p—56/153 (36.6%)152/153 (99.3%)
Most frequent serious events
Showing 10 of 182
Most frequent serious events
EventMPR+RMPR+pMPp+p
Febrile neutropeniaBlood and lymphatic system disorders9/1502/1520/153
PneumoniaInfections and infestations4/1508/1528/153
AnaemiaBlood and lymphatic system disorders5/1508/1522/153
PyrexiaGeneral disorders6/1502/1527/153
NeutropeniaBlood and lymphatic system disorders6/1504/1521/153
Deep vein thrombosisVascular disorders1/1506/1520/153
Bone painMusculoskeletal and connective tissue disorders3/1502/1526/153
Atrial fibrillationCardiac disorders1/1503/1525/153
FatigueGeneral disorders4/1502/1521/153
VomitingGastrointestinal disorders4/1501/1523/153
Most frequent other events
Showing 10 of 49
Most frequent other events
EventMPR+RMPR+pMPp+p
NeutropeniaBlood and lymphatic system disorders117/150116/15278/153
ThrombocytopeniaBlood and lymphatic system disorders103/150100/15268/153
AnaemiaBlood and lymphatic system disorders99/15091/15282/153
LeukopeniaBlood and lymphatic system disorders54/15058/15249/153
FatigueGeneral disorders46/15051/15257/153
NauseaGastrointestinal disorders37/15039/15251/153
Bone painMusculoskeletal and connective tissue disorders46/15045/15251/153
ConstipationGastrointestinal disorders49/15039/15237/153
DiarrhoeaGastrointestinal disorders43/15036/15237/153
RashSkin and subcutaneous tissue disorders30/15042/15212/153

Baseline characteristics

Age, Continuous
Age, Continuous(years)MPR+RMPR+pMPp+pTotal
Mean72.0 ± 5.3372.1 ± 5.2072.0 ± 5.2672.0 ± 5.25
Age, Customized
Age, Customized(participants)MPR+RMPR+pMPp+pTotal
<=75 years116116116348
>75 years363738111
Gender
Gender(Participants)MPR+RMPR+pMPp+pTotal
Female817179231
Male718275228
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)MPR+RMPR+pMPp+pTotal
White151151151453
Black1001
Hispanic0011
Asian / Pacific Islander0000
American Indian or Alaska Native0000
Other0224
Weight
Weight(kilograms)MPR+RMPR+pMPp+pTotal
Mean73.5 ± 14.7772.0 ± 12.7972.1 ± 15.2072.5 ± 14.28
Height
Height(centimeter)MPR+RMPR+pMPp+pTotal
Mean164.8 ± 9.81165.3 ± 9.33165.7 ± 9.79165.3 ± 9.63
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)MPR+RMPR+pMPp+pTotal
Mean133.9 ± 17.71135.5 ± 18.60136.4 ± 20.13135.3 ± 18.83
Diastolic Blood Pressure
Diastolic Blood Pressure(mmHg)MPR+RMPR+pMPp+pTotal
Mean78.5 ± 9.5377.4 ± 9.9978.8 ± 10.4078.2 ± 9.98

10 further baseline measures are reported on the registry.

08

Study locations

98 sites
  • Hematology Oncology Clinics of Australia, Level 5, Mater Medical Centre
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital Institute of Medical and Veterinary Science
    Adelaide, South Australia 5000, Australia
  • Royal Prince Alfred Hospital
    Camperdown, 2050, Australia
  • Peter MacCallum Cancer Centre Divsion of Haematology Medical Oncology
    East Melbourne, 3006, Australia
  • Frankston Hospital
    Frankston, 3199, Australia
  • The Alfred Hospital
    Melbourne, 3141, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, 6009, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • University Hospital Innsbruck
    Innsbruck, 6020, Austria
  • University Hospital of Salzburg St Johanns Spital
    Salzburg, 5020, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • Wilhelminenspital
    Vienna, 1160, Austria
  • Medical University of Vienna
    Vienna, A-1090, Austria
  • Republican Scientific and Practical Centre of Radiation Medicine and Human Ecology
    Gomel, 246 042, Belarus
  • City Clinical Hospital 9
    Minsk, 220116, Belarus
  • AZ St-Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • AZ-VUB
    Brussels, 1090, Belgium
  • UZ Gasthuisberg
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege
    Liege, 4000, Belgium
  • Fakultni nemocnice Brno
    Brno, 625 00, Czech Republic
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czech Republic
  • Fakultni Nemocnice Olomouc
    Olomouc, 77520, Czech Republic
  • Vseobecna Fakultni Nemocnice v Praze
    Prague, 128 081, Czech Republic
  • Hæmatologisk afd. B Aalborg Sygehus Syd
    Aalborg, 9000, Denmark
  • Medicinsk afd. Vejle Sygehus
    Vejle, 7100, Denmark
  • CHU
    Caen, 14033, France
  • CH - Hôpital Dupuytren
    Limoges Cedex 1, 87042, France
  • CHU Montpellier- Hopital Lapeyronie
    Montpellier Cedex 5, 34295, France
  • Assistance Publique - Hôpitaux de Paris AP-HP
    Paris, 75475, France
  • CHU Purpan
    Toulouse cedex 9, TSA 40031-31059, France
  • Ltd M.Zodelava Hematology Centre
    Tbilisi, 0112, Georgia
  • Institute of Hematology and Transfusiology
    Tbilisi, 0177, Georgia
  • Medizinische Klinik und Poliklinik II der Charite Campus Mitte
    Berlin, 10117, Germany
  • Universitatsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, D-01307, Germany
  • Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik
    Freiburg, D-79106, Germany
  • Ernst-Moritz-Arndt-Universität Greifswald
    Greifswald, 17487, Germany
  • Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V
    Heidelberg, 69120, Germany
  • Medizinische Klinik und Poliklinik II
    Leipzig, D-04103, Germany
  • Poliklinik A
    Münster, 47589, Germany
  • Medizinische Klinik - Abteilung II
    Tübingen, 72076, Germany
  • Medizinische Universitatsklinik
    Ulm, 89081, Germany
  • Medizinische Klinik und Poliklinik II des Universitatsklinikums Wurzburg
    Würzburg, 97080, Germany
  • G. GENNIMATAS General Hospital of Athens Department of Hematolgosy
    Athens, 115 27, Greece
  • General Air Force Hospital
    Athens, 11525, Greece
  • Alexandra General Hospital of Athens
    Athens, 11528, Greece
  • Hope Directorate Haematology Oncology Service St. James Hospital
    Dublin, 8, Ireland
  • Midlands Regional
    Tullamore / Co Offally, Ireland
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Hadassah University Hospital
    Jerusalem, 91120, Israel
  • Hematology Institute, Hemato-Oncology Division,Davidoff Cancer Center, Rabin MC Beilinson Hospital
    Petch Tikva, 49100, Israel
  • The Chaim Sheba Medical Center
    Tel Hashomer, 52621, Israel
  • Policlinico S. Orsola
    Bologna, 40138, Italy
  • A.O.U. San Martino
    Genova, 16132, Italy
  • Dipartmento Oncologico Struttura Complessa di ematlologiaA.O. Ospedale Niguarda Ca Granda
    Milano, 20162, Italy
  • Policlinico San Matteo Universita Di Pavia
    Pavia 2, 27100, Italy
  • Divisione Di Ematologia Ospedale Cattedra di Ematologia
    Rome, 00144, Italy
  • Azienda Policlinico Umberto I, Universita La Sapienzadi Roma
    Rome, 00161, Italy
  • Dipartimento di Onco-Ematologia
    San Giovanni Rotondo (FG), 71013, Italy
  • Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista
    Turin, 10126, Italy
  • VU Medical Center
    Amsterdam, 1081 HV, Netherlands
  • Erasmus Medical Center
    Rotterdam, 3015 GD/3000 CA, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, Netherlands
  • Klinika Hematologii Samodzielny Publiczny Szpital Kliniczny Akademii
    Bialystok, 15-276, Poland
  • Institute of Internal Diseases University of Medicine
    Gdansk, 80-211, Poland
  • Oddzial Kliniczny Kliniki Hematologii
    Krakow, 31-501, Poland
  • Uniwersytet Medyczny w Lodzi
    Lodz, 93-509, Poland
  • University School of Medicine
    Lublin, 20-290, Poland
  • Akademia Medyczna w Warszawie Samodzielny Publiczny Centralny Szpital Kliniczny
    Warsaw, 02-097, Poland
  • Burdenko Central Military Clinical Hospital
    Moscow, 105229, Russian Federation
  • Institution of Russian Academy of Medical Sciences Russian Oncological Research Centre n.a. N. N. Bl
    Moscow, 115678, Russian Federation
  • Moscow Regional Research Institute n.a. Vladimirsky
    Moscow, 129110, Russian Federation
  • Novosibirsk State Regional Clinical Hospital
    Novosibirsk, 630087, Russian Federation
  • Medical Radiological Research Center RAMS
    Obninsk, 249036, Russian Federation
  • Samara Regional Clinical Hospital
    Samara, 443095, Russian Federation
  • St. Petersburg Research Institute of Hematology and Blood Transfusion
    St. Petersburg, 191024, Russian Federation
  • Hospital Clinic
    Barcelona, 08036, Spain
  • Hospital Universitaro Puerta del MarServicio de Hematologia
    Cadiz, 11009, Spain
  • Hospital Universitario de la Princessa
    Madrid, 28006, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Virgen del Rocio Servicio de Hematologia
    Sevilla, 41013, Spain
  • Medicinkliniken
    Boras, 501 82, Sweden
  • Medicinska kliniken
    Malmö, 20502, Sweden
  • UniversitatsSpital ZurichKlinik fur Onkologie
    Zurich, CH-8091, Switzerland
  • Ankara University
    Ankara, 06620, Turkey
  • Marmara School of Medicine
    Istanbul, 34662, Turkey
  • Ege University Medical School
    Izmir, 35100, Turkey
  • Cherkassy Regional Oncology Center
    Cherkassy, 18009, Ukraine
  • Dnepropetrovsk City Clinical Hospital 4
    Dnepropetrovsk, 49044, Ukraine
  • Institute of Urgent and Recovery Surgery
    Donetsk, 83047, Ukraine
  • Institute of Hematology and Transfusiology of the UAMS Department of blood diseases
    Kiev, 04060, Ukraine
  • Institute of Blood Pathology and Transfusion Medicine of the AMS of Ukraine
    Lviv 79044, Ukraine
  • Zhitomir Regional Clinical Hospital
    Zhitomir, 10003, Ukraine
  • Monklands Hospital
    Aidrie, ML6 0JS, United Kingdom
  • St James's University Hospital
    Leeds, LS7 9TF, United Kingdom
  • University College London Hospitals Cancer Clinical Trials Unitist FloorCentral wing
    London, NW1 2PG, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
  • Christie NHS Trust Hospital
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Dimopoulos MA, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013 May;98(5):784-8. doi: 10.3324/haematol.2012.074534. Epub 2012 Dec 14. PubMed 23242595 ↗
  • Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. Erratum In: N Engl J Med. 2012 Jul 19;367(3):285. PubMed 22571200 ↗
  • Dimopoulos MA, Petrucci MT, Foa R, Catalano J, Kropff M, Terpos E, Zhang J, Grote L, Jacques C, Palumbo A; MM-015 Investigators. Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. Haematologica. 2015 Aug;100(8):e328-30. doi: 10.3324/haematol.2014.120790. Epub 2015 Apr 3. No abstract available. PubMed 25840600 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Nov 2009 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2006
First posted
Nov 30, 2006
Start
Jan 2007
Primary completionActual
Nov 2009
CompletionActual
Apr 2016
Results first posted
May 11, 2012
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00405756
Responsible party
Sponsor
First posted
Nov 30, 2006
Start date
Jan 2007
Primary completion
Nov 2009
Completion
Apr 2016
Results posted
May 11, 2012
Last update
Jan 11, 2017

Study contacts

Antonio Palumbo, M.D.
principal investigator · Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion